- Staat
- OH
- Alter
- 24,0
- Geschlecht
- M
- Eingang
- 14.06.2023
- Impfdatum
- 14.06.2023
- Beginn
- 14.06.2023
- Tage bis Beginn
- 0,0
- Dosis
- 3
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: ja
Erholt: ja
Face injury
Facial bones fracture
Fall
Loss of consciousness
Symptomtext
Patient passed out and hit the floor with his face after second vaccine was given. He was speaking with the nurse when she turned around to get a paper off the counter and she heard him fall.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Loss of consciousness
- Hospital-Tage
- -
- Labordaten
- EMS was called. They came and evaluated him and took him via ambulence to the hospital to evaluate his broken nose.
- Aktuelle Erkrankungen
- n/a
- Vorgeschichte
- none
- Andere Medikamente
- n/a
- Allergien
- nkda
- Vorherige Impfungen
- -
- Staat
- KS
- Alter
- 31,0
- Geschlecht
- M
- Eingang
- 06.07.2023
- Impfdatum
- 06.07.2023
- Beginn
- 06.07.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Dizziness
Hyperhidrosis
Malaise
Musculoskeletal stiffness
Paraesthesia
Symptomtext
pt was dizzy, he said head was not feeling well, stiff hand, sweating. he said legs are tingly . right arm was tingly (even tho pt had vaccin in left arm)... after 20 mins pt said he is feeing better
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Paraesthesia
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- n/a
- Vorgeschichte
- n/a
- Andere Medikamente
- -
- Allergien
- n/a
- Vorherige Impfungen
- -
- Staat
- IL
- Alter
- 47,0
- Geschlecht
- F
- Eingang
- 24.05.2023
- Impfdatum
- 12.04.2023
- Beginn
- 13.04.2023
- Tage bis Beginn
- 1,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Blood magnesium normal
Blood test normal
Differential white blood cell count normal
Hypoaesthesia
Magnetic resonance imaging normal
Metabolic function test normal
Muscle spasms
Paraesthesia
Vitamin B12 normal
Symptomtext
Patient reports that approximately 24-48 hours after receiving 3 vaccines (Hepatitis B, Tdap & Typhoid) that she began feeling numbness/tingling/cramping in right arm and right foot for which she believe is attributable to the hepatitis B vaccine. She also received a 2nd booster/4th dose of Covid-19 Vaccine (Pfizer lot#GL0087) on 4/13/2023 at the Health Department. Symptoms did not progress any further and have since resolved over the past 1 month. However, they were great enough to cause her to visit her primary care physician for further follow-up. Her PCP ordered a MRI and bloodwork (CBC with Auto Differential, vitamin B12, CMP Comprehensive, Assay Magnesium). All testing came back normal per PCP. On 5/22/2023, she had her 2nd dose of Hepatitis B for which she has experienced the same symptoms to her left arm and left foot. After discussion with her PCP he encouraged her to let us know she was having symptoms. As of today, 5/24/2023, she feels the symptoms are starting to resolve. No further testing for this incident has been done at this time beyond reporting and will continue to monitor for complete resolution of symptoms.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Paraesthesia
- Hospital-Tage
- -
- Labordaten
- MRI and bloodwork (CBC with Auto Differential, vitamin B12, CMP Comprehensive, Assay Magnesium)
- Aktuelle Erkrankungen
- No
- Vorgeschichte
- None
- Andere Medikamente
- Omeprazole Supplements: Calcium, Turmeric, Vitamin D, Vitamin E, Magnesium, Probiotic, Multi Vitamins.
- Allergien
- Fish - Nausea
- Vorherige Impfungen
- -
- Staat
- TX
- Alter
- 40,0
- Geschlecht
- F
- Eingang
- 06.02.2023
- Impfdatum
- 06.02.2023
- Beginn
- 06.02.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Paraesthesia oral
Tongue pruritus
Symptomtext
10:45am as client was leaving, she stated that her lips were alittle tingly . came back in to clinic and waited then she complained that her tongue was a little itchy. 11:00am Gave Benadryl 50mg IM to right arm. sat in clinic x 30 mins. during that time, she did say she was better, just tired called a family member to pick her up.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Paraesthesia oral
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- IN
- Alter
- -
- Geschlecht
- F
- Eingang
- 19.10.2023
- Impfdatum
- 14.08.2023
- Beginn
- -
- Tage bis Beginn
- -
- Dosis
- 1
- Route/Site
- SYR / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Exposure during pregnancy
Fatigue
Maternal exposure before pregnancy
Nausea
Symptomtext
Patient received vaccine on 14-AUG-2023 and learned she was pregnant on 16-SEP-2023; Patient reports no symptoms or side effects; This spontaneous prospective report was received from a nurse, referring to a currently 38-year-old female patient without known allergies. Her concurrent conditions included polycystic ovarian syndrome. The patient's medical history and concomitant therapies were not reported. The patient's last menstrual period was on 25-JUL-2023. Later, on 14-AUG-2023, the patient presented to reporter's clinic to receive immigration vaccines and was vaccinated with: varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, first dose, lot #X006979 with expiration date on 07-MAR-2025, administered subcutaneously in left arm (dose not provided); measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection, first dose, lot # X005838 with expiration date on 03-JUN-2024, administered subcutaneously in left arm (dose not provided); and hepatitis b vaccine, lot # reported as NT9X3 with expiration date on 09-SEP-2024, administered intramuscularly in left arm (dose not provided). By that time, the patient was asked if she was planning on becoming pregnant or if she was pregnant, and answered no to both questions. No pregnancy tests were performed prior to vaccines administration. On 22-AUG-2023, the patient noticed she missed her period and learned she became pregnant on 16-SEP-2023 (exposure during pregnancy). Therefore, on 19-SEP-2023, she presented to clinic and informed the reporter about pregnancy status. No treatment was given to the patient. By the time of the report, pregancy outcome was pending and the fetal outcome was unknown. Additionally, she had not seen an obstetric provider, but was scheduled for first visit in December 2023. No symptoms, side effects or complaints were reported. The estimated date of delivery would be on 30-APR-2024. Lot number X005838 has been verified to be a valid lot number for measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II).
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Fatigue
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- Polycystic ovarian syndrome; Prophylaxis
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- CA
- Alter
- 54,0
- Geschlecht
- F
- Eingang
- 01.03.2023
- Impfdatum
- 28.02.2023
- Beginn
- 28.02.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Dizziness
Headache
Posture abnormal
Symptomtext
At 0958 hrs, after vaccinating patient ( 54 Y/O female), with Hepatitis B and Influenza, patient slumped in chair but did not lose consciousness. Patient reported feeling dizzy with headache 6/10; patient also reported history of headaches. LVN took VS at 100:00 am and were BP165/90, HR 79. Patient then reported she had been fasting since 2/27/2023. She was offered Emergency Medical Services but denied them. She denied previous vaccine reaction to vaccines and major health issues. At 10:05 am VS were BP 158/81, HR 79. Patient then stated headache pain level to be 4/10. PHN Supervisor was notified of the situation. 10:20 am VS were 161/77, HR 79. At this time, patient reported that the dizziness and headache diminished. Final VS 10:35 am were BP 124/76, HR 63. Patient remained alert and oriented through the entire event. LVN advised patient to follow up with PCP and for husband to observe for any changes in condition. 10:50 AM pATIENT DEPARTED CLINIC WITH HUSBAN.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Dizziness
- Hospital-Tage
- -
- Labordaten
- no
- Aktuelle Erkrankungen
- UNKNOWN
- Vorgeschichte
- UNKNOWN
- Andere Medikamente
- Tylenol
- Allergien
- NKA
- Vorherige Impfungen
- -
- Staat
- KS
- Alter
- 38,0
- Geschlecht
- F
- Eingang
- 31.01.2023
- Impfdatum
- 25.01.2023
- Beginn
- 26.01.2023
- Tage bis Beginn
- 1,0
- Dosis
- 3
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Eyelid skin dryness
Eyelids pruritus
Symptomtext
States the next day late afternoon she noticed itching to both eyelids. The right eyelid was worse than the left. The itch feeling continued into the weekend. Today (01/31/2023 Tuesday) is she is better and denies any itchy feeling but does state eyelids feel dry.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Eyelids pruritus
- Hospital-Tage
- -
- Labordaten
- None
- Aktuelle Erkrankungen
- Week before sinus congestion
- Vorgeschichte
- None
- Andere Medikamente
- NoneAll
- Allergien
- None
- Vorherige Impfungen
- -
- Staat
- NY
- Alter
- 63,0
- Geschlecht
- F
- Eingang
- 26.01.2023
- Impfdatum
- 25.01.2023
- Beginn
- 25.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 3
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Dizziness
Fatigue
Throat irritation
Symptomtext
fatigue, itchy throat, dizziness
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Dizziness
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- unknown
- Vorgeschichte
- has multiple chronic medical conditions
- Andere Medikamente
- Potassium chloride, Advair diskus, albuterol, Eliquis, hydrochlorothiazide, fluticasone, folic acid, diltiazem
- Allergien
- seasonal allergies, Enalapril, Bactrim tabs
- Vorherige Impfungen
- -
- Staat
- NM
- Alter
- 25,0
- Geschlecht
- F
- Eingang
- 11.01.2023
- Impfdatum
- 30.11.2022
- Beginn
- 30.11.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Urticaria
Symptomtext
Patient states the night of the first vaccine she noticed hives on bilateral forearms. She also mentioned she takes medication for her blood pressure and was unsure if the combination of the medication and the vaccine caused the reaction. She took Benadryl and the hives subsided and she has not had an issue since.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Urticaria
- Hospital-Tage
- -
- Labordaten
- None. Patient was given a declination form to sign to decline any further Hepatitis vaccines from our clinic.
- Aktuelle Erkrankungen
- Hypertension
- Vorgeschichte
- Hypertension
- Andere Medikamente
- Hydrochlorothiazide, Losartan,
- Allergien
- Seasonal allergies. NKMA
- Vorherige Impfungen
- -
- Staat
- NM
- Alter
- 44,0
- Geschlecht
- M
- Eingang
- 09.12.2022
- Impfdatum
- 19.10.2022
- Beginn
- 28.10.2022
- Tage bis Beginn
- 9,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: ja
Erholt: ja
Rash
Urticaria
Symptomtext
Patient reported developing hives and rash on bilateral forearms, anterior legs, chest and back. Reported going to emergency room for reaction.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Rash
- Hospital-Tage
- -
- Labordaten
- Unknown.
- Aktuelle Erkrankungen
- None reported
- Vorgeschichte
- None reported
- Andere Medikamente
- None reported
- Allergien
- None reported
- Vorherige Impfungen
- -
- Staat
- PR
- Alter
- 22,0
- Geschlecht
- F
- Eingang
- 30.11.2022
- Impfdatum
- 08.11.2022
- Beginn
- 15.11.2022
- Tage bis Beginn
- 7,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Abdominal pain upper
Lymph node pain
Lymphadenopathy
Oropharyngeal pain
Tongue discolouration
Symptomtext
Today November 30, 2022 patient contacts us and verbalizes by phone that a week after administering the vaccine she presents pain in the lymph nodes and swelling, abdominal pain right side near the liver, yellowish tongue and sore throat.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Abdominal pain upper
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- Patient Verbalizes suffering from bipolarity, fatty liver and heart disease in the aorta.
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MD
- Alter
- 31,0
- Geschlecht
- F
- Eingang
- 22.10.2022
- Impfdatum
- 07.10.2022
- Beginn
- 18.10.2022
- Tage bis Beginn
- 11,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Injection site erythema
Injection site swelling
Joint stiffness
Pain
Pruritus
Urticaria
Symptomtext
Redness and swelling at injection site approx 1 week after vaccine, worsening with increasingly spreading welts all over body. Itching, joint stiffness, pain
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Injection site erythema
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- N/A
- Vorgeschichte
- N/A
- Andere Medikamente
- Sertraline
- Allergien
- Penicillin
- Vorherige Impfungen
- -
- Staat
- NC
- Alter
- 52,0
- Geschlecht
- F
- Eingang
- 19.10.2023
- Impfdatum
- 01.08.2022
- Beginn
- 28.02.2023
- Tage bis Beginn
- 211,0
- Dosis
- 1
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Inappropriate schedule of product administration
Serology abnormal
Therapy non-responder
Symptomtext
due to test showing low to no titers; received 2nd dose on 28 Feb 2023 and 3rd dose in 5/1/2023; received 1st dose in Aug 2022 and 2nd in Feb 2023; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of therapy non-responder in a 52-year-old female patient who received HBV (Engerix B adult) for prophylaxis. Co-suspect products included HBV (Engerix B adult) (batch number NT9X3, expiry date 09-SEP-2024) for prophylaxis and HBV (Engerix B adult) (batch number NT9X3, expiry date 09-SEP-2024) for prophylaxis. On 01-MAY-2023, the patient received the 3rd dose of Engerix B adult. On 28-FEB-2023, the patient received the 2nd dose of Engerix B adult. In AUG-2022, the patient received the 1st dose of Engerix B adult. On 28-FEB-2023, not applicable after receiving Engerix B adult and Engerix B adult and an unknown time after receiving Engerix B adult, the patient experienced drug dose administration interval too long (Verbatim: received 1st dose in Aug 2022 and 2nd in Feb 2023). On 01-MAY-2023, the patient experienced drug dose administration interval too short (Verbatim: received 2nd dose on 28 Feb 2023 and 3rd dose in 5/1/2023). On an unknown date, the patient experienced therapy non-responder (Verbatim: due to test showing low to no titers). The outcome of the therapy non-responder, drug dose administration interval too long and drug dose administration interval too short were unknown. Additional Information: GSK Receipt date: 09-OCT-2023 A pharmacist reported a patient was there to receive a dose of Engerix. RPH explained that last year the patient received 2 shots (separate not same day) of Engerix around August 2022 (RPH was unaware of these), then one dose on 28 February 2023, and another Engerix on 01 May 2023. HCP mentioned the patient stated they changed jobs and the job was requiring restart series due to test showing low to no titers. Patient came in today for potentially another dose of Engerix. What to do. The patient received 2nd dose of Engerix later than the recommended interval, which led to lengthening of the vaccine schedule. The patient received 3rd dose of Engerix shorter than the recommended interval, which led to shortening the vaccine schedule. The reporter did not consent to follow-up.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Inappropriate schedule of product administration
- Hospital-Tage
- -
- Labordaten
- Test Name: serology test; Result Unstructured Data: (Test Result:showing low to no titers,Unit:unknown,Normal Low:,Normal High:)
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- NC
- Alter
- 52,0
- Geschlecht
- F
- Eingang
- 19.10.2023
- Impfdatum
- 01.08.2022
- Beginn
- 28.02.2023
- Tage bis Beginn
- 211,0
- Dosis
- 2
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Inappropriate schedule of product administration
Serology abnormal
Therapy non-responder
Symptomtext
due to test showing low to no titers; received 2nd dose on 28 Feb 2023 and 3rd dose in 5/1/2023; received 1st dose in Aug 2022 and 2nd in Feb 2023; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of therapy non-responder in a 52-year-old female patient who received HBV (Engerix B adult) for prophylaxis. Co-suspect products included HBV (Engerix B adult) (batch number NT9X3, expiry date 09-SEP-2024) for prophylaxis and HBV (Engerix B adult) (batch number NT9X3, expiry date 09-SEP-2024) for prophylaxis. On 01-MAY-2023, the patient received the 3rd dose of Engerix B adult. On 28-FEB-2023, the patient received the 2nd dose of Engerix B adult. In AUG-2022, the patient received the 1st dose of Engerix B adult. On 28-FEB-2023, not applicable after receiving Engerix B adult and Engerix B adult and an unknown time after receiving Engerix B adult, the patient experienced drug dose administration interval too long (Verbatim: received 1st dose in Aug 2022 and 2nd in Feb 2023). On 01-MAY-2023, the patient experienced drug dose administration interval too short (Verbatim: received 2nd dose on 28 Feb 2023 and 3rd dose in 5/1/2023). On an unknown date, the patient experienced therapy non-responder (Verbatim: due to test showing low to no titers). The outcome of the therapy non-responder, drug dose administration interval too long and drug dose administration interval too short were unknown. Additional Information: GSK Receipt date: 09-OCT-2023 A pharmacist reported a patient was there to receive a dose of Engerix. RPH explained that last year the patient received 2 shots (separate not same day) of Engerix around August 2022 (RPH was unaware of these), then one dose on 28 February 2023, and another Engerix on 01 May 2023. HCP mentioned the patient stated they changed jobs and the job was requiring restart series due to test showing low to no titers. Patient came in today for potentially another dose of Engerix. What to do. The patient received 2nd dose of Engerix later than the recommended interval, which led to lengthening of the vaccine schedule. The patient received 3rd dose of Engerix shorter than the recommended interval, which led to shortening the vaccine schedule. The reporter did not consent to follow-up.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Inappropriate schedule of product administration
- Hospital-Tage
- -
- Labordaten
- Test Name: serology test; Result Unstructured Data: (Test Result:showing low to no titers,Unit:unknown,Normal Low:,Normal High:)
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MD
- Alter
- 50,0
- Geschlecht
- F
- Eingang
- 20.09.2023
- Impfdatum
- 13.09.2023
- Beginn
- 13.09.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Inappropriate schedule of product administration
Symptomtext
Inappropriate Schedule of Vaccine; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 50-year-old female patient who received HBV (Engerix B adult) (batch number NT9X3, expiry date 09-SEP-2024) for prophylaxis. Previously administered products included Engerix B adult (1st dose received on 28th June 2023). On 13-SEP-2023, the patient received the 2nd dose of Engerix B adult. On 13-SEP-2023, an unknown time after receiving Engerix B adult, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate Schedule of Vaccine). The outcome of the drug dose administration interval too long was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-SEP-2022 The patient received 2nd dose of Engerix B adult, later than the recommended interval, which led to lengthening of vaccination schedule. The reporter consented to follow up.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Inappropriate schedule of product administration
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- NE
- Alter
- 17,0
- Geschlecht
- F
- Eingang
- 07.07.2023
- Impfdatum
- 07.07.2023
- Beginn
- 07.07.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
No adverse event
Symptomtext
At the time of administration no signs or symptoms were shown. Vaccination was given at 2:10 pm on 7/7/2023.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- NC
- Alter
- 55,0
- Geschlecht
- F
- Eingang
- 19.06.2023
- Impfdatum
- 16.06.2023
- Beginn
- 16.06.2023
- Tage bis Beginn
- 0,0
- Dosis
- 3
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Inappropriate schedule of product administration
Symptomtext
Dose #3 was administered to early. Pt was supposed to be scheduled for a lab collection not vaccine administration.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Inappropriate schedule of product administration
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- Isentress (take 1 BID) raltegravir 400 mg tablet (one tab by mouth bid) Truvada Search Truvada 200 mg-300 mg tablet (1 daily)
- Allergien
- NKDA
- Vorherige Impfungen
- -
- Staat
- OH
- Alter
- 59,0
- Geschlecht
- F
- Eingang
- 08.06.2023
- Impfdatum
- 12.12.2022
- Beginn
- 14.12.2022
- Tage bis Beginn
- 2,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Immunisation reaction
Symptomtext
Adverse effect of other vaccines and biological substances, initial encounter on 2022-12-14.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Immunisation reaction
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- Allergic rhinitis, unspecified; Acute cystitis with hematuria; Pain NOS; Special screening examination for infections with a predominantly sexual mode of transmission; Body mass index [BMI] 31.0-31.9, adult; Unspecified fall, initial encounter; Type 2 diabetes mellitus without complications; Sprain of unspecified site of right knee, initial encounter; Need for immunization against single bacterial diseases; Body mass index [BMI] 30.0-30.9, adult
- Vorgeschichte
- -
- Andere Medikamente
- CYCLOBENZAPRINE HCL 5 MG ORAL TABS
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- TX
- Alter
- -
- Geschlecht
- F
- Eingang
- 18.05.2023
- Impfdatum
- 15.03.2023
- Beginn
- 15.03.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Inappropriate schedule of product administration
Symptomtext
Engerix B + Early 3rd dose; Engerix B Late 2nd dose and 3rd dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 55-year-old female patient who received HBV (Engerix B) (batch number NT9X3, expiry date 09-SEP-2024) and (batch number 9JG23, expiry date 10-FEB-2025) for prophylaxis. Co-suspect products included HBV (Engerix B) (batch number 9JG23, expiry date 10-FEB-2025) for prophylaxis. Previously administered products included engerix B (received 1st dose in November 2021). On 15-MAR-2023, the patient received the 2nd dose of Engerix B. On 17-APR-2023, the patient received the 3rd dose of Engerix B. On 15-MAR-2023, an unknown time after receiving Engerix B and not applicable after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: Engerix B Late 2nd dose and 3rd dose). On 17-APR-2023, the patient experienced drug dose administration interval too short (Verbatim: Engerix B + Early 3rd dose). The outcome of the drug dose administration interval too long and drug dose administration interval too short were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 16-May-2023 Medical assistant reported that a female patient received a first dose of Engerix B in November 2021, a second dose on 15th March 2023, which led to later than the recommended schedule, which led to shortening of the vaccination schedule. The patient also received third dose on 17th April 2023, which led earlier than the recommended standard schedule, which led to shortening of the vaccination schedule. The reporter asked how to proceed and safety information on early 3rd dose. The reporter did not consent to follow-up. The Vaccine Administration Facility was the same as Primary Reporter.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Inappropriate schedule of product administration
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- NY
- Alter
- -
- Geschlecht
- F
- Eingang
- 13.05.2023
- Impfdatum
- 08.05.2023
- Beginn
- 08.05.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Product administered to patient of inappropriate age
Symptomtext
Adult dose to a 4 day-old patient; Adult dose to a 4 day-old patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 4-day-old female patient who received HBV (Engerix B) (batch number NT9X3, expiry date 09-SEP-2024) for prophylaxis. On 08-MAY-2023, the patient received Engerix B. On 08-MAY-2023, an unknown time after receiving Engerix B, the patient experienced adult product administered to child (Verbatim: Adult dose to a 4 day-old patient) and overdose (Verbatim: Adult dose to a 4 day-old patient). The outcome of the adult product administered to child and overdose were unknown. Additional Information: GSK Receipt Date: 8-MAY-2023. A nurse called in to report the administration of an Engerix adult dose to a 4 day-old patient. The health care professional asked for safety information about this situation. The reporter consented to follow up. Engerix adult dose administered to a 4 day-old patient which led to adult product administered to child and and overdose.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product administered to patient of inappropriate age
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- OH
- Alter
- -
- Geschlecht
- U
- Eingang
- 01.05.2023
- Impfdatum
- 27.02.2023
- Beginn
- -
- Tage bis Beginn
- -
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Product storage error
Symptomtext
Received vaccines after a temperature excursion; This non-serious case was reported by a other health professional and described the occurrence of incorrect storage of drug in a 27-year-old patient who received Hepatitis B vaccine (batch number NT9X3) for prophylaxis. On 27-FEB-2023, the patient received Hepatitis B vaccine. On an unknown date, an unknown time after receiving Hepatitis B vaccine, the patient experienced incorrect storage of drug (Verbatim: Received vaccines after a temperature excursion). The outcome of the incorrect storage of drug was unknown. Additional Information: GSK receipt date: 14-Apr-2023 The reporter consented to follow-up. This case is for one of 119 patients, reported by same reporter. The patient received unstable vaccine after a temperature excursion, which led to incorrect storage of drug.; Sender's Comments: US-GSK-US2023054677:same reporter US-GSK-US2023AMR055743:same reporter
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product storage error
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- IL
- Alter
- 46,0
- Geschlecht
- M
- Eingang
- 24.03.2023
- Impfdatum
- 24.03.2023
- Beginn
- 24.03.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Product administration error
Symptomtext
Received an unnecessary dose of Hepatitis B.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product administration error
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- Diabetes Essential HTN
- Vorgeschichte
- -
- Andere Medikamente
- Tradjenta atorvastatin metformin enalapril
- Allergien
- none
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 53,0
- Geschlecht
- F
- Eingang
- 23.03.2023
- Impfdatum
- 29.11.2022
- Beginn
- 29.11.2022
- Tage bis Beginn
- 0,0
- Dosis
- 4
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Unevaluable event
Symptomtext
Hepatitis B vaccine was given to person with chronic hepatitis B disease
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Unevaluable event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MI
- Alter
- 73,0
- Geschlecht
- M
- Eingang
- 01.03.2023
- Impfdatum
- 01.03.2023
- Beginn
- 01.03.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Underdose
Symptomtext
Client inadvertently admin'd HepB- peds dose. Brought client back from waiting room to inform them and admin adult HepB dose
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Underdose
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- Cirrhosis
- Andere Medikamente
- -
- Allergien
- NKA
- Vorherige Impfungen
- -
- Staat
- NC
- Alter
- 19,0
- Geschlecht
- F
- Eingang
- 06.02.2023
- Impfdatum
- 31.01.2023
- Beginn
- 31.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Product administered to patient of inappropriate age
Symptomtext
Engerix- adult was given to 19-year old; Engerix- adult was given to 19-year old; This case was reported by a other health professional via call center representative and described the occurrence of overdose in a 19-year-old female patient who received HBV (Engerix B adult) (batch number NT9X3, expiry date 9th September 2024) for prophylaxis. On 31st January 2023, the patient received Engerix B adult. On 31st January 2023, unknown after receiving Engerix B adult, the patient experienced overdose and inappropriate age at vaccine administration. On an unknown date, the outcome of the overdose and inappropriate age at vaccine administration were unknown. Additional Information: GSK Receipt Date: 31-JAN-2023 Reporter's Comment: The healthcare professional reported that the patient received a dose of Engerix B adult. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. Additional Supportive Information: The 19 years old patient received an adult Engerix B dose, which led to overdose and inappropriate age at vaccine administration.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product administered to patient of inappropriate age
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- TX
- Alter
- 12,0
- Geschlecht
- M
- Eingang
- 25.01.2023
- Impfdatum
- 17.01.2023
- Beginn
- 17.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Overdose
Product administered to patient of inappropriate age
Symptomtext
Adult dose given to a 12 year-old; Adult dose given to a 12 year-old; This case was reported by a nurse via call center representative and described the occurrence of overdose in a 12-year-old male patient who received HBV (Engerix B adult) (batch number NT9X3, expiry date 9th September 2024) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. On 17th January 2023, the patient received Engerix B adult and Engerix B Pre-Filled Syringe Device. On 17th January 2023, unknown after receiving Engerix B adult and Engerix B Pre-Filled Syringe Device, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose and adult product administered to child were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 17-Jan-2023 Reporter's comment: Nurse administered Engerix-B adult dose to 12 year old pediatric patient. Adverse event contains all reported information. The reporter gave consent for safety team follow-up. The reporter consented to follow-up. Additional supportive information: The pediatric patient received an adult dose of Engerix-B, which led to overdose and adult product administered to child.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Overdose
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- TX
- Alter
- 13,0
- Geschlecht
- M
- Eingang
- 17.01.2023
- Impfdatum
- 17.01.2023
- Beginn
- 17.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Incorrect dose administered
Product administered to patient of inappropriate age
Symptomtext
Patient arrived at Public Health Services with his Grandmother for vaccines. Scheduled vaccines are as follows: Hep B, Polio, and TD. Administered TD. Polio and Hep B not administered at the time due to not having any in stock. While administering other vaccines to his siblings, the vaccines arrived. Vaccines were being dispensed into system by LVN. I obtained a Hep B vaccine. I thought all the vaccines box were for program only, since we were completely out of Hep B, Hep A, IPV, and Varicella. I thought it was an emergency shipment. While administering Hep B to the patient, I noticed that it was more than .5 ml. I went to verify with LVN and he informed me that there was other vaccines in the box as well. I then seen that I had administered an adult dose to patient. His weight is 134 lbs. Patient walked out in good spirits. No noticeable distress noted.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Incorrect dose administered
- Hospital-Tage
- -
- Labordaten
- N/A
- Aktuelle Erkrankungen
- N/A
- Vorgeschichte
- N/A
- Andere Medikamente
- N/A
- Allergien
- NKA
- Vorherige Impfungen
- -
- Staat
- NE
- Alter
- -
- Geschlecht
- M
- Eingang
- 21.12.2022
- Impfdatum
- 07.12.2022
- Beginn
- 07.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Incorrect dose administered
Product administered to patient of inappropriate age
Symptomtext
Pediatric patient received adult dose; Pediatric patient received adult dose; This case was reported by a nurse via call center representative and described the occurrence of accidental overdose in a 5-year-old male patient who received HBV (Engerix B adult) (batch number NT9X3, expiry date 9th September 2024) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. On 7th December 2022, the patient received the 1st dose of Engerix B adult and Engerix B Pre-Filled Syringe Device. On 7th December 2022, unknown after receiving Engerix B adult and Engerix B Pre-Filled Syringe Device, the patient experienced accidental overdose and adult product administered to child. On an unknown date, the outcome of the accidental overdose and adult product administered to child were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-DEC-2022 Reporter's Comments: Registered nurse called in to report that a pediatric patient was wrongfully administered the adult dose of Engerix-B on 7th December 2022. The event took place at the site from where the report was made. Patients information was also disclosed. The reporter consented to follow up. The Vaccine Administration Facility was the same as Primary Reporter. Additional Supportive Information: the pediatric patient was wrongfully administered the adult dose of Engerix-B, which led to accidental overdose and Adult product administered to child.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Incorrect dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- IA
- Alter
- 30,0
- Geschlecht
- M
- Eingang
- 14.12.2022
- Impfdatum
- 13.12.2022
- Beginn
- 13.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- 3
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Extra dose administered
No adverse event
Symptomtext
Patient presented for Physical. Vaccines were updated. Patient had already completed MMR series prior to appointment. Patient was given an extra dose of MMR. No adverse reactions noted.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- none
- Vorgeschichte
- none
- Andere Medikamente
- none
- Allergien
- NKA
- Vorherige Impfungen
- -
- Staat
- MN
- Alter
- 19,0
- Geschlecht
- F
- Eingang
- 12.12.2022
- Impfdatum
- -
- Beginn
- -
- Tage bis Beginn
- -
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Accidental overdose
Product administered to patient of inappropriate age
Symptomtext
19 year old patient received Engerix B adult; 19 year old received Engerix B adult; This case was reported by a other health professional via call center representative and described the occurrence of accidental overdose in a 19-year-old female patient who received HBV (Engerix B adult) (batch number NT9X3, expiry date 9th September 2024) for prophylaxis. On an unknown date, the patient received Engerix B adult. On an unknown date, unknown after receiving Engerix B adult, the patient experienced accidental overdose and inappropriate age at vaccine administration. On an unknown date, the outcome of the accidental overdose and inappropriate age at vaccine administration were unknown. Additional Information: GSK Receipt Date: 30-NOV-2022 Reporter's Comment: The medical assistant reported that a 19 year old patient was inadvertently administered an adult dose of Engerix-B. The vaccine administration facility was the same as primary reporter. The reporter consent to follow up via email. Additional supportive information: The patient was inadvertently administered an adult dose of Engerix-B, which led to overdose and inappropriate age at vaccine administration.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Accidental overdose
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- -
- Alter
- 17,0
- Geschlecht
- M
- Eingang
- 21.11.2022
- Impfdatum
- 11.11.2022
- Beginn
- 11.11.2022
- Tage bis Beginn
- 0,0
- Dosis
- 3
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Product administered to patient of inappropriate age
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product administered to patient of inappropriate age
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- NA
- Vorgeschichte
- NA
- Andere Medikamente
- NA
- Allergien
- NA
- Vorherige Impfungen
- -
- Staat
- -
- Alter
- 13,0
- Geschlecht
- M
- Eingang
- 21.11.2022
- Impfdatum
- 15.11.2022
- Beginn
- 15.11.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Unevaluable event
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Unevaluable event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- NA
- Vorgeschichte
- NA
- Andere Medikamente
- Vitamin D3, Iron-Folic Acid
- Allergien
- NKA
- Vorherige Impfungen
- -
- Staat
- IL
- Alter
- 12,0
- Geschlecht
- M
- Eingang
- 31.10.2022
- Impfdatum
- 13.10.2022
- Beginn
- 13.10.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Incorrect dose administered
No adverse event
Symptomtext
Patient presented requesting Hep B Vaccination. When looking up Energix I read information on energix recombivax and thought it was discussing Energix. Patient was given adult dose instead of pediatric dose around 2:45 pm. Patients family has been notified and has not reported any adverse events since the vaccine administration.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Incorrect dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MN
- Alter
- 19,0
- Geschlecht
- F
- Eingang
- 26.10.2022
- Impfdatum
- 26.10.2022
- Beginn
- 26.10.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
No adverse event
Product administered to patient of inappropriate age
Wrong product administered
Symptomtext
HEP B vac was ordered and given. Hep A Havrix was also given and not ordered. It is a vaccine approved for 12-18years. No Adverse events took place. No side effects or reactions noted. Patient left clinic without issue and in no acute distress.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- none
- Vorgeschichte
- none
- Andere Medikamente
- none
- Allergien
- none
- Vorherige Impfungen
- -